| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
During the last three months, 13 analysts shared their evaluations of Inspire Medical Systems (NYSE:INSP), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 7 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 3 | 5 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Inspire Medical Systems, revealing an average target of $148.23, a high estimate of $230.00, and a low estimate of $97.00. Observing a downward trend, the current average is 25.28% lower than the prior average price target of $198.38.
The analysis of recent analyst actions sheds light on the perception of Inspire Medical Systems by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Kratky | Leerink Partners | Lowers | Market Perform | $97.00 | $116.00 |
| Mike Kratky | Leerink Partners | Lowers | Market Perform | $116.00 | $149.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $125.00 | $190.00 |
| Frank Takkinen | Lake Street | Lowers | Buy | $150.00 | $270.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Equal-Weight | $101.00 | $174.00 |
| Danielle Antalffy | UBS | Lowers | Buy | $230.00 | $270.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $180.00 | $215.00 |
| Jonathan Block | Stifel | Lowers | Hold | $140.00 | $175.00 |
| Adam Maeder | Piper Sandler | Lowers | Overweight | $150.00 | $233.00 |
| Robbie Marcus | JP Morgan | Lowers | Neutral | $110.00 | $195.00 |
| Brett Fishbin | Keybanc | Lowers | Overweight | $197.00 | $216.00 |
| Kallum Titchmarsh | Morgan Stanley | Lowers | Overweight | $182.00 | $200.00 |
| Mike Kratky | Leerink Partners | Lowers | Market Perform | $149.00 | $176.00 |
For valuable insights into Inspire Medical Systems's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Inspire Medical Systems analyst ratings.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Inspire Medical Systems's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.82% as of 30 June, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Inspire Medical Systems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -1.65%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Inspire Medical Systems's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.55% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Inspire Medical Systems's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.47%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: INSP
